Triglycerides: Risk factor or fellow traveler?

Current Opinion in Cardiology

Volumn 16, Issue 4, 2001, Pages 261-264

  Forrester, James S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TRIACYLGLYCEROL;

CLINICAL TRIAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FATTY ACID METABOLISM; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; RISK FACTORS; TRIGLYCERIDES;

EID: 0034864668     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200107000-00007     Document Type: Review

References (27)

1. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
2. Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the carotid artery
3. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness
4. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides
5. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as do smaller macromolecules, including low-density lipoprotein, high-density lipoprotein and albumn
6. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
7. Epidemiology of triglycerides: A view from Framingham
8. New and classical risk factors-the Munster heart study (PROCAM)
9. Plasma triglyceride and coronary heart disease
10. Plasma triglyceride as a risk factor for coronary heart disease: The epidemiologic evidence and beyond
11. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
12. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men
13. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
14. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
15. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
16. How deadly is the deadly quartet?
17. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
18. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients
19. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
20. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
21. Conclusions from the VA-HIT study
22. Fenofibrate reduces progression of coronary artery disease for people with type 2 diabetes
23. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
24. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients
25. Primary prevention of coronary heart disease in women through diet and lifestyle
26. Secondary prevention of coronary heart disease: The role of fibric acids
27. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders